Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients

Claudia Arena1
Giuseppe Troiano1
Khrystyna Zhurakivska1
Riccardo Nocini2
Lorenzo Lo Muzio1,3

1Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; 2Section of Otolaryngology, Department of Surgical Sciences, Dentistry, Gynecology, and Pediatrics, University of Verona, Verona, Italy; 3C.I.N.B.O. (Consorzio Interuniversitario Nazionale per la Bio-Oncologia), Chieti, Italy

Background: Oral toxicities, such as mucositis and stomatitis, are some of the most significant and unavoidable side effects associated with anticancer therapies. In past decades, research has focused on newer targeted agents with the aim of decreasing the rates of side effects on healthy cells. Unfortunately, even targeted anticancer therapies show significant rates of toxicity on healthy tissue. mTOR inhibitors display some adverse events, such as hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities, and mucocutaneous eruption, but the most important are still stomatitis and skin rash, which are often dose-limiting side effects.

Aim: This review was performed to answer the question “What is the incidence of stomatitis in patients treated with everolimus?”

Methods: We conducted a systematic search on the PubMed and Medline online databases using a combination of MESH terms and free text: “everolimus” (MESH) AND “side effects” OR “toxicities” OR “adverse events”. Only studies fulfilling the following inclusion criteria were considered eligible for inclusion in this study: performed on human subjects, reporting on the use of everolimus (even if in combination with other drugs or ionizing radiation), written in the English language, and reporting the incidence of side effects.

Results: The analysis of literature revealed that the overall incidence of stomatitis after treatment with everolimus was 42.6% (3,493) and that of stomatitis grade G1/2 84.02% (2,935), while G3/4 was 15.97% (558).

Conclusion: Results of the analysis showed that the incidence of stomatitis of grade 1 or 2 is higher than grade 3 or 4. However, it must be taken into account that it is not possible to say if side effects are entirely due to everolimus therapy or combinations with other drugs.

Keywords: stomatitis, everolimus, mucositis, targeted therapy, oral medicine, oral pathology

Introduction

Conventional anticancer therapy does not distinguish between normal and cancer cells. The damage inflicted on normal tissue have thus hampered this therapy.1 The introduction of targeted-therapy molecules targeting specific enzymes, growth-factor receptors, and signal transducers has lowered the incidence of side effects,2 significantly influencing patient quality of life and survival rates.3 mTOR is a therapeutic target for both solid and hematologic malignancies. It is part of a pathway that regulates protein biosynthesis, cell growth, and cell-cycle progression. Moreover, mTOR is the downstream effector of the PI3K–Akt–mTOR pathway, which regulates cell growth and metabolism and is involved in multiple processes.1,3–5

Rapamycin and its analogues form the first generation of mTOR inhibitors. The action of these molecules is targeting a 289 kDa serine/threonine-protein kinase that
is a component of the big family of PI3Ks. Rapamycin and its analogues work by inhibiting the activity of mTORC1 through binding to FKBP12 and the establishment of a ternary complex with mTOR. Actually, there are three available mTOR inhibitors: everolimus, temsirolimus, and ridaforolimus. Everolimus is currently used for the treatment of advanced hormone receptor–positive HER2-negative breast cancer together with exemestane, renal-cell carcinoma after failure of therapies based on sunitinib or sorafenib, progressive neuroendocrine tumors of pancreatic origin, in combination with exemestane, and subependymal giant-cell astrocytoma.

These drugs have a different spectrum of side effects compared to conventional chemotherapy. Common side effects are anemia, fatigue, hyperglycemia, hyperlipidemia, stomatitis, rash, and thrombocytopenia. The terms "oral mucositis" and "stomatitis" are both used to describe inflammation and ulceration of the oral mucosal lining due to chemotherapy or ionizing radiation. However, stomatitis associated with mTOR inhibitors should be considered a separate entity this often being designated as mTOR inhibitor–associated stomatitis (mIAS). Mouth lesions present as superficial, ovoid, well-demarcated singular or multiple ulcers with a grayish white pseudomembrane. Their size often does not exceed 0.5 cm in diameter. Lesions typically involve the nonkeratinized mucosa, like the inner aspect of the lips, the ventral and lateral surfaces of the tongue, and the soft palate. Ulcers generally develop in 5 days and usually heal spontaneously in 1 week, most frequently in the first cycle of mTOR-inhibitor therapy.

**Methods**

This review was performed to answer to the question “Which is the rate of incidence of stomatitis in patients treated with everolimus?” A systematic search on the online databases PubMed and Medline was conducted using a combination of MESH terms and free-text words: “everolimus” (MESH) AND “side effects” OR “toxicities” OR “adverse events”. The authors included in this study only reports that fulfilled certain criteria: performed on human subjects, everolimus alone or in combination with other drugs/ionizing radiation, written in the English language, and providing incidence of side effects. No restrictions were applied on year of publication. Reviews, case reports, and studies in vitro or performed on animal models were excluded. Information collected comprised name of first author, year, title, number of patients enrolled, and number and grade of events recorded. In addition, data were independently extracted by two authors (CA and LLM) and checked in a joint session.

**Results**

Our literature search yielded 1,019 potentially relevant studies. After elimination of duplicates, titles and abstracts of 912 potentially relevant studies were screened. Of these, 731 were not considered because they did not meet the inclusion criteria. A total of 181 studies were read in full text. Of these, only 100 reported on stomatitis or oral mucositis, and 30 were excluded due to lack of data (Figure 1). Results showed that the overall incidence of stomatitis after treatment with everolimus was 42.6% (3,493), stomatitis grade G1 84.02% (2,935), and G34 15.97% (558, Table 1).

**Discussion**

Targeted therapy includes those drugs that selectively inhibit a target that is mutated in malignant tissue, aiming to achieve preferential localization in the region of disease and thus an increase in local concentration. In particular, mTOR inhibitors work as signal-transduction inhibitors. Rapamycin, also named sirolimus, was the first mTOR inhibitor approved. It is an antiinflammatory produced by Streptomyces hygroscopicus with immunosuppressive properties. However, sirolimus has been show to have
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Title</th>
<th>Therapy</th>
<th>Patients, n</th>
<th>Stomatitis, n (%)</th>
<th>G1/2, n (%)</th>
<th>G3/4, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amato et al</td>
<td>2009</td>
<td>A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer</td>
<td>Everolimus at a dose of 10 mg daily orally without interruption (28-day cycle), with dose modifications for toxicity (graded according to National Cancer Institute Common Toxicity Criteria version 3.0). Patients were evaluated every two cycles (8 weeks) using Response Evaluation Criteria in Solid Tumors (RECIST)</td>
<td>39</td>
<td>12 (30.8)</td>
<td>G1 4 (10.3)</td>
<td>G2 8 (20.5)</td>
</tr>
<tr>
<td>Andre et al</td>
<td>2014</td>
<td>Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial</td>
<td>In this randomised, double-blind, placebo-controlled, phase III trial, authors recruited women with HER2-positive, trastuzumab-resistant advanced breast carcinoma who had previously received taxane therapy. Eligible patients were randomly assigned (1:1) using a central patient-screening and randomization system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m²) or to placebo plus trastuzumab plus vinorelbine, in 3-week cycles, stratified by previous lapatinib use</td>
<td>280</td>
<td>175 (62)</td>
<td>138 (49)</td>
<td>G3 37 (13)</td>
</tr>
</tbody>
</table>
| Angelousi et al | 2017 | Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments       | A: 20 1st-line everolimus  
| Armstrong et al | 2016 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPen — a multicentre, open-label, randomised phase 2 trial) | Everolimus orally at 10 mg once daily                                                                                                                                                                                                                                                                                                        | 52          | 27 (48)          | 22 (39)     | G3 5 (9)    |
| Bajetta et al  | 2014 | Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors | Treatment-naive patients with advanced well-differentiated NETs of gastroenteropancreatic tract and lung origin received everolimus 10 mg daily in combination with octreotide LAR 30 mg every 28 days                                                                                                                                                                                                 | 50          | 31 (62)          | 26 (52)     | G3 4 (8)    |
Table 1 (Continued).

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Title</th>
<th>Therapy</th>
<th>Patients, n</th>
<th>Stomatitis, n (%)</th>
<th>G1/2, n (%)</th>
<th>G3/4, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baselga et al</td>
<td>2012</td>
<td>Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer</td>
<td>Double-blind phase III study, patients randomly assigned to treatment with oral everolimus or matching placebo (10 mg daily) in conjunction with exemestane (25 mg daily)</td>
<td>482</td>
<td>56 (11.61)</td>
<td>48 (9.95)</td>
<td>G3 8</td>
</tr>
<tr>
<td>Baselga et al</td>
<td>2009</td>
<td>Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer</td>
<td>270 postmenopausal women with operable ER-positive breast cancer were randomly assigned to receive 4 months of neoadjuvant treatment with letrozole (2.5 mg/day) and either everolimus (10 mg/day) or placebo</td>
<td>137</td>
<td>50 (36.5)</td>
<td>47 (34.3)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Bergmann et al</td>
<td>2015</td>
<td>Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study</td>
<td>Patients received everolimus 10 mg once daily until disease progression or unacceptable</td>
<td>334</td>
<td>22 (7)</td>
<td>18 (81)</td>
<td>4 (18)</td>
</tr>
<tr>
<td>Besse et al</td>
<td>2014</td>
<td>Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer</td>
<td>Everolimus 5 mg/day + erlotinib 150 mg/day</td>
<td>66</td>
<td>48 (72.6)</td>
<td>G1 11 (16.7)</td>
<td>G3 21 (31.8)</td>
</tr>
<tr>
<td>Campone et al</td>
<td>2009</td>
<td>Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours</td>
<td>Everolimus was dose-escalated from 15 to 30 mg and administered with paclitaxel 80 mg/m$^2$ on days 1, 8, and 15 every 28 days</td>
<td>16</td>
<td>6 (37.5)</td>
<td>5 (31.25)</td>
<td>G3 1 (6.25)</td>
</tr>
<tr>
<td>Castellano et al</td>
<td>2013</td>
<td>Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study</td>
<td>Everolimus plus octreotide</td>
<td>19</td>
<td>11 (57.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choueiri et al</td>
<td>2013</td>
<td>A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor</td>
<td>Patients treated with temozolomide 150 mg/m$^2$ per day on days 1–7 and 15–21 in combination with everolimus daily in each 28-day cycle. In cohort 1, temozolomide was administered together with everolimus at 5 mg daily. Following demonstration of safety in this cohort, subsequent patients in cohort 2 were treated with temozolomide plus everolimus at 10 mg daily</td>
<td>43</td>
<td>27</td>
<td>G1 22 (51)</td>
<td>G3 1 (2)</td>
</tr>
<tr>
<td>Choueiri et al</td>
<td>2015</td>
<td>Cabozantinib versus everolimus in advanced renal cell carcinoma</td>
<td>Everolimus at a dose of 10 mg daily</td>
<td>322</td>
<td>77 (24)</td>
<td>70 (21.7)</td>
<td>7 (2.2)</td>
</tr>
<tr>
<td>Reference</td>
<td>Year</td>
<td>Treatment</td>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>-----------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chow et al</td>
<td>2016</td>
<td>Oral bicalutamide 50 mg and oral everolimus 10 mg, both once daily, with a cycle defined as 4 weeks</td>
<td>24</td>
<td>14 (58.3)</td>
<td>10 (41.6)</td>
<td>G3 4</td>
<td></td>
</tr>
<tr>
<td>Chung et al</td>
<td>2016</td>
<td>Six patients were accrued to the first dose level of 2.5 mg everolimus daily with mFOLFOX6</td>
<td>A: 6</td>
<td>4 (66)</td>
<td>G1 2 (33)</td>
<td>G3 2 (33)</td>
<td></td>
</tr>
<tr>
<td>Ciruelos et al</td>
<td>2017</td>
<td>Eligible patients started study treatment on day 1 with daily doses of everolimus (2/5/9 mg or 1/9/10 mg) and exemestane (25 mg) and continued until disease progression or unacceptable toxicity</td>
<td>429</td>
<td>272 (63)</td>
<td>232 (54)</td>
<td>G3 40 (9)</td>
<td></td>
</tr>
<tr>
<td>Ciunci et al</td>
<td>2014</td>
<td>Patients received oral everolimus 10 mg daily and letrozole 2.5 mg daily</td>
<td>19</td>
<td>2 (10.5)</td>
<td>-</td>
<td>G3 2 (10.5)</td>
<td></td>
</tr>
<tr>
<td>Colon-Otero et al</td>
<td>2017</td>
<td>Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at three dose levels of everolimus with docetaxel: 5–60 mg/m², 10–60 mg/m², and 10–70 mg/m². The primary end point was the safety and tolerability of combination therapy.</td>
<td>18</td>
<td>5 (27.7)</td>
<td>5 (27.7)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Deenen et al</td>
<td>2012</td>
<td>Fixed-dose everolimus 10 mg/day continuously plus capecitabine twice daily for 14 days in 3-weekly cycles</td>
<td>18</td>
<td>9 (50)</td>
<td>9 (50)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Doi et al</td>
<td>2010</td>
<td>Everolimus 10 mg orally daily</td>
<td>A: 53</td>
<td>3 (5.7)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Elmadani et al</td>
<td>2017</td>
<td>Everolimus + sorafenib</td>
<td>26</td>
<td>6 (23.1)</td>
<td>6 (23.1)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Escudier et al</td>
<td>2016</td>
<td>Oral everolimus 10 mg once daily until disease progression or unacceptable toxicity</td>
<td>92</td>
<td>23 (25)</td>
<td>23 (25)</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Title</th>
<th>Therapy</th>
<th>Patients, n</th>
<th>Stomatitis, n (%)</th>
<th>G1/2, n (%)</th>
<th>G3/4, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fazio et al(^{50})</td>
<td>2013</td>
<td>Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study</td>
<td>Everolimus + octreotide</td>
<td>33</td>
<td>3 (9.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Ferolla et al\(^{51}\) | 2017 | Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial | A: everolimus  
B: everolimus + pasireotide  
Total A: 30 (72)  
Total B: 15 (37)  
A: 26 (62)  
B: 13 (32)  
A: G3 4  
B: G3 2 (5) |             |                  |             |             |
| Finn et al\(^{52}\)    | 2013 | Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma | A: sorafenib + everolimus 2.5 mg once daily  
B: sorafenib + everolimus 5 mg once daily  
Ulcers total 6 (37.5) | 30          | 11 (39)          | 11 (39)     |             |
<p>| Fury et al(^{53})    | 2012 | A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors | Not reported                                                                                                                            |             |                  |             |             |
| Ghobrial et al(^{54}) | 2010 | Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia | Everolimus 10 mg daily for two cycles                                                                                                   | 50          | 4 (8)             | 4 (8)       |             |
| Goldberg et al(^{55}) | 2015 | Everolimus for the treatment of lymphangieliomyomatosis: a phase II study | Not reported                                                                                                                           | 24          | 18 (75)           |             |             |
| Gong et al(^{56})    | 2017 | Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study | Everolimus was usually initiated at 10 mg or in some instances 5 mg daily, according to patients' tolerance and request               | 70          | 40 (57.1)         | 34 (47.8)   | G3 6 (9.3)  |
| Grignani et al(^{57}) | 2015 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial | A: patients took 400 mg sorafenib twice a day together with 5 mg everolimus once a day                                                   | 38          | 20 (100)          | G1 11 (29)  | G2 7 (18)   | G3 2 (5) |
| Hainsworth et al(^{58}) | 2010 | Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma | All patients received bevacizumab 10 mg/kg intravenously every 2 weeks and everolimus 10 mg orally daily                              | 80          | 48 (60)           | 36 (45)     | G3 12 (15)  |</p>
<table>
<thead>
<tr>
<th>Author et al</th>
<th>Year</th>
<th>Study Description</th>
<th>Treatment Details</th>
<th>Key Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hatano et al</td>
<td>2016</td>
<td>Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: a single institution experience in Japan</td>
<td>Everolimus set at 10 mg once a day for adults</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43 (91)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42 (97.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (2.3)</td>
</tr>
<tr>
<td>Hatano et al</td>
<td>2017</td>
<td>Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex</td>
<td>Everolimus set at 10 mg once a day</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23 (88)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Hurvitz et al</td>
<td>2013</td>
<td>A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy</td>
<td>Everolimus 10 mg/day in combination with paclitaxel (80 mg/m² days 1, 8, and 15 every 4 weeks) and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), administered in 28-day cycles</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42 (76.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G1 13 (23.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G2 18 (32.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G3 11 (20)</td>
</tr>
<tr>
<td>Jerusalem et al</td>
<td>2016</td>
<td>Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)</td>
<td>Not reported</td>
<td>2,131</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,126 (52.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>926 (43.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G3 198 (9.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G4 2 (0.1)</td>
</tr>
<tr>
<td>Jovanovic et al</td>
<td>2017</td>
<td>A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status and Ki67</td>
<td>Not reported</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>37 (39)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>37 (39)</td>
</tr>
<tr>
<td>Jozwik et al</td>
<td>2016</td>
<td>Safety of everolimus in patients younger than 3 years of age: results from EXIST-I, a randomized, controlled clinical trial</td>
<td>Everolimus initiated at 4.5 mg/m²/day and titrated to blood trough levels of 5–15 ng/mL</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 (66.7)</td>
</tr>
<tr>
<td>Kato et al</td>
<td>2014</td>
<td>Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment</td>
<td>Not reported</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7 (37)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 (32)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (5)</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Title</td>
<td>Therapy</td>
<td>Patients, n</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Kim et al[6]</td>
<td>2014</td>
<td>A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma</td>
<td>Everolimus given at 10 mg daily until progression or occurrence of unacceptable toxicities</td>
<td>34</td>
</tr>
<tr>
<td>Kim et al[6]</td>
<td>2018</td>
<td>Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: a multicentre study in Korea</td>
<td>Everolimus</td>
<td>36</td>
</tr>
<tr>
<td>Koutsoukos et al[68]</td>
<td>2017</td>
<td>Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib</td>
<td>Not reported</td>
<td>31</td>
</tr>
</tbody>
</table>
| Kulke et al[69]       | 2017 | A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial | A: everolimus + pasireotide LAR  
B: everolimus | A: 78  
B: 81 | A: 46 (59)        | A: 39 (50)  | A: 7 (9)      |
<p>| | | | | | | | |
|                       |      |                                                                       |                                                                         |             |                  |             |             |
| Kumano et al[70]      | 2013 | Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors | Everolimus                                                             | 57          | 17 (29.8)        | 14 (82.35) | 3 (5.3)     |
| Moscetti et al[71]    | 2016 | Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: a multicenter Italian experience | Not reported                                   | 181         | 115 (63.5)       | G1 54 (29.8) | G3 15 (8.3) |
| Motzer et al[72]      | 2016 | Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)[2] | Not reported                                   | 133         | 7 (5.26)         |             |             |</p>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Study Description</th>
<th>Treatment Details</th>
<th>Total</th>
<th>progression</th>
<th>Response</th>
<th>Grade</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motzer et al</td>
<td>2008</td>
<td>Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</td>
<td>Everolimus 10 mg once daily</td>
<td>269</td>
<td>107 (40)</td>
<td>98 (36.43)</td>
<td>G3</td>
<td>9</td>
</tr>
<tr>
<td>Motzer et al</td>
<td>2015</td>
<td>Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial</td>
<td>Everolimus 10 mg day</td>
<td>50</td>
<td>21 (42)</td>
<td>20 (40)</td>
<td>G3</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Oh et al</td>
<td>2012</td>
<td>Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas</td>
<td>Everolimus was administered daily at a dose of 10 mg for 4 weeks.</td>
<td>34</td>
<td>6 (17.6)</td>
<td>4 (11.7)</td>
<td>2 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Ohtsu et al</td>
<td>2013</td>
<td>Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-I study</td>
<td>Everolimus 10 mg/day + BSC</td>
<td>437</td>
<td>174 (40)</td>
<td>154 (35)</td>
<td>20 (5)</td>
<td></td>
</tr>
<tr>
<td>Ohyama et al</td>
<td>2017</td>
<td>Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial</td>
<td>Not reported</td>
<td>A 53</td>
<td>26 (49.1)</td>
<td>22 (41.6)</td>
<td>4 (7.5)</td>
<td></td>
</tr>
<tr>
<td>Panzuto et al</td>
<td>2014</td>
<td>Real-world study of everolimus in advanced progressive neuroendocrine tumors</td>
<td>Everolimus</td>
<td>169</td>
<td>37 (21.9)</td>
<td>33 (19.6)</td>
<td>4 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Park et al</td>
<td>2014</td>
<td>Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor</td>
<td>Everolimus</td>
<td>100</td>
<td>42 (44)</td>
<td>36 (38)</td>
<td>6 (6)</td>
<td></td>
</tr>
<tr>
<td>Pavel et al</td>
<td>2016</td>
<td>Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimus</td>
<td>Not reported</td>
<td>123</td>
<td>29 (23.6)</td>
<td>23 (18.7)</td>
<td>G3</td>
<td>6 (4.9)</td>
</tr>
<tr>
<td>Quek et al</td>
<td>2011</td>
<td>Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors</td>
<td>Figitumumab (20 mg/kg IV every 21 days) with full-dose everolimus (10 mg orally once daily)</td>
<td>21</td>
<td>21 (100)</td>
<td>G1 11 (52.4)</td>
<td>G2 7 (33.3)</td>
<td>G3 3 (14.3)</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued).

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Title</th>
<th>Therapy</th>
<th>Patients, n</th>
<th>Stomatitis, n (%)</th>
<th>G1/2, n (%)</th>
<th>G3/4, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safra et al^82</td>
<td>2018</td>
<td>Everolimus plus letrozole for treatment of patients with HR^+, HER2^- advanced breast cancer progressing on endocrine therapy: an open-label, phase II trial</td>
<td>Everolimus 10 mg daily and letrozole 2.5 mg daily</td>
<td>72</td>
<td>39 (54.2)</td>
<td>18 (45.9)</td>
<td>G3 21 (8.3)</td>
</tr>
<tr>
<td>Salazar et al^83</td>
<td>2017</td>
<td>Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor-naïve advanced pancreatic neuroendocrine tumors</td>
<td>Everolimus 10 mg once daily</td>
<td>31</td>
<td>20 (64.5)</td>
<td>18 (58)</td>
<td>2 (6.5)</td>
</tr>
<tr>
<td>Sarkaria et al^84</td>
<td>2011</td>
<td>NCCTG phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patients</td>
<td>All patients received weekly oral RAD001 in combination with standard chemoradiotherapy, followed by RAD001 in combination with standard adjuvant temozolomide</td>
<td>18</td>
<td>11 (61.1)</td>
<td>G2 11 (61.1)</td>
<td></td>
</tr>
<tr>
<td>Strickler et al^85</td>
<td>2012</td>
<td>Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors</td>
<td>10 mg panobinostat three times weekly, 5 or 10 mg everolimus daily, and bevacizumab at 10 mg/kg every 2 weeks</td>
<td>12</td>
<td>4 (33)</td>
<td>3 (25)</td>
<td>1 (8)</td>
</tr>
</tbody>
</table>
| Sun et al^86            | 2013 | A phase Ib study of everolimus plus paclitaxel in patients with small-cell lung cancer | A: everolimus 2.5 mg 6  
B: everolimus 5 mg 11  
C: everolimus 10 mg 3 | 20          | 8 (40)             | A 2 (10)    | B 5 (25)    | C 1 (5)     |
<p>| Takahashi et al^87      | 2013 | Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results | Everolimus 1.5 mg/day starting dose (target trough 3–8 ng/mL) + reduced-dose cyclosporine | 61          | 14 (2.3)          | G1 3 (23.7) | G2 4 (30.7) |
| Tobinai et al^88        | 2010 | Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma everolimus 5 or 10 mg orally once daily | Not reported                                                            | 13          | 7 (53.7)          | G1 3 (23.7) | G2 4 (30.7) |
| Vlahovic et al^89       | 2012 | A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors | Everolimus and flat dosing of panitumumab at 4.8 mg/kg and bevacizumab at 10 mg/kg every 2 weeks | 32          | 24 (76)           | 20 (63)     | 4 (13)      |
| Wang et al^90           | 2014 | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study | Not reported                                                            | 58          | 12 (20.7)         | 11 (19)     | G3 1 (1.7)  |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Treatment Description</th>
<th>Number</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Werner et al&lt;sup&gt;91&lt;/sup&gt;</td>
<td>2013</td>
<td>Oral everolimus (5, 7.5, and 10 mg/day) in combination with intravenous MMC 5 mg/m² every 3 weeks.</td>
<td>16</td>
<td>9 (56.25)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolpin et al&lt;sup&gt;92&lt;/sup&gt;</td>
<td>2009</td>
<td>Everolimus 10 mg daily</td>
<td>33</td>
<td>10 (30)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yao et al&lt;sup&gt;93&lt;/sup&gt;</td>
<td>2008</td>
<td>RAD001 5 mg/day or 10 mg/day and octreotide LAR 30 mg every 28 days</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yao et al&lt;sup&gt;94&lt;/sup&gt;</td>
<td>2011</td>
<td>10 mg once daily</td>
<td>204</td>
<td>131 (64)</td>
<td>117 (57)</td>
<td>14 (7)</td>
<td></td>
</tr>
<tr>
<td>Yee et al&lt;sup&gt;95&lt;/sup&gt;</td>
<td>2006</td>
<td>Not reported</td>
<td>27</td>
<td>10 (37)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total over all</td>
<td></td>
<td></td>
<td>8,201</td>
<td>3,490 (42.55)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total with grade</td>
<td></td>
<td></td>
<td>7,796</td>
<td>3,347 (42.93)</td>
<td>2,839 (36.41)</td>
<td>508 (6.51)</td>
<td></td>
</tr>
</tbody>
</table>
poor pharmacokinetic characteristics, and research has focused on the synthesis of analogues of rapamycin more suitable to therapy, such as everolimus, temsirolimus, and ridaforolimus. These molecules differ from sirolimus in their C-40-O positions, resulting in disparate pharmacokinetic and pharmacodynamic profiles. This class of drugs is typically used for the treatment of solid tumors, such as renal-cell carcinoma, breast cancer, pancreatic neuroendocrine tumors, and tuberous sclerosis complex.

Unlike results obtained from reviews about mucositis caused by conventional chemotherapy, in which mucositis is often severe and the most debilitating effect for patients, our analysis showed that the incidence of stomatitis of grade 1 or 2 is higher than that of grade 3 or 4. These results are consistent with our previous work. However, it must be taken into account that it is not possible to say if side effects are entirely due to everolimus therapy or combination with other drugs. Moreover, not all the papers included in this review specified the exact therapeutic regimen. mIAS generally sets in within a few weeks of initiating everolimus therapy. Grade 3 or 4 lesions may lead to dose interruption or reduction. Interfering with patient food intake and diminishing quality of life, this kind of toxicity may cause treatment discontinuation or interruption.

mIAS is often evaluated using common scales employed in the evaluation of conventional oral mucositis (OMAS, 1999; NCI-CTCAE 2006, 2010). However, its clinical appearance tends to differ from conventional mucositis. A more specific mIAS scale was set by Boers-Doets and Lalla. According to this scale, lesions are evaluated depending on their duration, eg, a grade 3 lesion is an ulceration lasting >7 days. Management of mIAS is still widely based on education of patients on oral hygiene measures, diet modifications, and pain management.

Treatments used are often based on “magic” mouthwash, composed of lidocaine gel 2% × 30 g, doxycycline suspension 50 mg/5mL × 60 mL, and sucralfate oral suspension 1,000 mg/5 mL dissolved in sodium chloride 0.9% × 2,000 mL used for 3–15 days, a sodium bicarbonate–based mouthwash combined with oral flucanazole, or a combination of dexamethasone solution 0.5 mg/mL and miconazole 2% gel. Another treatment is based on a combination of topical anesthetics, a magic mouthwash (composed of lidocaine, aluminum hydroxide, magnesium hydroxide, dimethicone suspension, diphenhydramine, equal parts) clobetasol gel 0.05%, dexamethasone 0.1 mg/mL, trimacinolone paste, intralesional trimacinolone, and systemic prednisone (1 mg/kg for 7 days). Management of mIAS nowadays is based on education of patients on oral hygiene measures, diet modifications, and pain management. Rugo et al showed evidence of the efficacy of a prophylactic use of dexamethasone mouthwash in patients treated with everolimus plus exemestane for advanced or metastatic breast cancer. The mouthwash was administered in combination with a prophylactic topical antifungal agent to prevent potential fungal infection. It cannot be determined which lesions will self-limit and which will reduce quality of life, leading to malnutrition and dose reduction in medically necessary treatment.

Disclosure

The authors report no conflicts of interest in this work.

References


OncoTargets and Therapy 2019:12

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management, survival and quality of life for cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.